tetano
Editor, Senior Moderator
Presse Med. 2018 Sep 12. pii: S0755-4982(18)30320-8. doi: 10.1016/j.lpm.2018.06.013. [Epub ahead of print]
[h=1][Quadrivalent influenza vaccine: What is changed and what are the benefits?][/h] [Article in French]
Mosnier A[SUP]1[/SUP], Launay O[SUP]2[/SUP], Martinez L[SUP]3[/SUP], Gavazzi G[SUP]4[/SUP], Josset L[SUP]5[/SUP], Crepey P[SUP]6[/SUP], Hannoun C[SUP]7[/SUP], Weil-Olivier C[SUP]8[/SUP], Gaillat J[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently, circulating viruses responsible for annual seasonal influenza epidemics belong to two influenza A subtypes, A(H1N1) and A(H3N2), and to two antigenically distinct type B lineages, B/Yamagata and B/Victoria lineages. Like diseases due to influenza A virus, influenza B virus diseases may have severe consequences and should be prevented. Until now, in France, the vaccines used to prevent seasonal influenza were trivalent, systematically targeting viruses belonging to both A subtypes and to one or other of the B lineages. The protective efficacy of trivalent vaccines is diminished during the seasons when viruses belonging to both B lineages cocirculated or when the circulating dominant type B virus belonged to a lineage different from that targeted by the vaccine strain. By targeting viruses belonging to both B lineages, quadrivalent vaccines improve the antigenic concordance between circulating and vaccine type B strains. Three inactivated quadrivalent vaccines are authorized for marketing in France and should be available for the 2018-2019 season. It is expected that, by providing enlarged protection, these quadrivalent influenza vaccines will improve vaccine efficacy, the confidence in immunization of the public, the satisfaction of health professionals, and ultimately will help to complete immunization coverage.
PMID: 30219205 DOI: 10.1016/j.lpm.2018.06.013
Free full text
[h=1][Quadrivalent influenza vaccine: What is changed and what are the benefits?][/h] [Article in French]
Mosnier A[SUP]1[/SUP], Launay O[SUP]2[/SUP], Martinez L[SUP]3[/SUP], Gavazzi G[SUP]4[/SUP], Josset L[SUP]5[/SUP], Crepey P[SUP]6[/SUP], Hannoun C[SUP]7[/SUP], Weil-Olivier C[SUP]8[/SUP], Gaillat J[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Currently, circulating viruses responsible for annual seasonal influenza epidemics belong to two influenza A subtypes, A(H1N1) and A(H3N2), and to two antigenically distinct type B lineages, B/Yamagata and B/Victoria lineages. Like diseases due to influenza A virus, influenza B virus diseases may have severe consequences and should be prevented. Until now, in France, the vaccines used to prevent seasonal influenza were trivalent, systematically targeting viruses belonging to both A subtypes and to one or other of the B lineages. The protective efficacy of trivalent vaccines is diminished during the seasons when viruses belonging to both B lineages cocirculated or when the circulating dominant type B virus belonged to a lineage different from that targeted by the vaccine strain. By targeting viruses belonging to both B lineages, quadrivalent vaccines improve the antigenic concordance between circulating and vaccine type B strains. Three inactivated quadrivalent vaccines are authorized for marketing in France and should be available for the 2018-2019 season. It is expected that, by providing enlarged protection, these quadrivalent influenza vaccines will improve vaccine efficacy, the confidence in immunization of the public, the satisfaction of health professionals, and ultimately will help to complete immunization coverage.
PMID: 30219205 DOI: 10.1016/j.lpm.2018.06.013
Free full text